Investigational drug · Phase 2
GNC-038
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-hodgkin's Lymphoma, Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
7
Any phase or sponsor naming "GNC-038"
First trial start
2022
Aug 10, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "GNC-038", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-hodgkin's Lymphoma
- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- Diffuse Large B-cell Lymphoma
- NK/T Cell Lymphoma
- Vascular Immunomother T Cell Lymphoma
- Non-Hodgkin Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hodgkin lymphoma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "GNC-038" as an intervention, largest first.
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Systemic Lupus ErythematosusRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06857214 · 84 participants (planned) · Start Jun 4, 2025 · Primary completion Dec 2027
Drug: GNC-038; Belimumab · For: Systemic Lupus Erythematosus
Sites: Shanghai, China
- A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid ArthritisRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06857227 · 54 participants (planned) · Start Mar 17, 2025 · Primary completion Dec 2027
Drug: GNC-038; Placebo · For: Rheumatoid Arthritis
Sites: Shanghai, China
- Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic LeukemiaActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT04606433 · 47 participants · Start Nov 4, 2020 · Primary completion Dec 2025
Drug: GNC-038 · For: Non Hodgkin Lymphoma; Acute Lymphoblastic Leukemia
Sites: Hefei, China; Beijing, China; Chongqing, China · 10 sites in all
- A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRecruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05623982 · 40 participants (planned) · Start Sep 26, 2022 · Primary completion Dec 2026
Drug: GNC-038 · For: Non-hodgkin's Lymphoma
Sites: Beijing, China; Haerbin, China; Qingdao, China
- A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)Active, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05192486 · 12 participants · Start Aug 10, 2022 · Primary completion Dec 2025
Drug: GNC-038 · For: Diffuse Large B-cell Lymphoma
Sites: Shenzhen, China; Baoding, China; Luoyang, China · 4 sites in all
- A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)Active, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05485753 · 7 participants · Start Feb 10, 2023 · Primary completion Dec 2025
Drug: GNC-038 · For: Primary Central Nervous System Lymphoma; Secondary Central Nervous System Lymphoma
Sites: Beijing, China; Guangzhou, China; Zhengzhou, China · 4 sites in all
- A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHLActive, not recruiting
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT05627856 · 4 participants · Start Feb 21, 2023 · Primary completion Dec 2025
Drug: GNC-038 · For: NK/T Cell Lymphoma; Vascular Immunomother T Cell Lymphoma; Non-Hodgkin Lymphoma
Sites: Guangzhou, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-hodgkin's Lymphoma
- single CNCT19Phase 23 trials
Juventas Cell Therapy Ltd. · Relapsed or Refractory Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma
- GNC-035Phase 22 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Relapsed/Refractory Chronic Lymphocytic Leukemia, Non-hodgkin's Lymphoma
- EB103Phase 21 trial
Estrella Immunopharma, Inc. · B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins, Lymphomas Non-Hodgkin's B-Cell
- MBS303Phase 21 trial
Beijing Mabworks Biotech Co., Ltd. · Non-Hodgkin's Lymphoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.